ArticleDiabetologia2025
Health economic evaluation of a risk-stratified intervention in diabetic kidney disease.
Article in Diabetologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Chronic Kidney Disease (CKD): Systematic Review of the Cost Effectiveness of SGLT2 Inhibitors and Other Novel Nephroprotective Drugs.PharmacoEconomics · 2026Pooled it
- Literature-informed ensemble machine learning for three-year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model.Diabetes, obesity & metabolism · 2026Article
- The Inflammatory Cell Death in Diabetic Kidney Disease: Integrating Multifactorial Mechanisms into Novel Therapeutics.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aims/hypothesisThe study aimed to model the progression of diabetic kidney disease (DKD) in a multi-ethnic Asian population and evaluate the economic impact of a risk-stratified intervention for DKD management.
methodsUsing the Singapore Diabetic Cohort (N=9660), multi-state Markov models were constructed to derive chronic kidney disease (CKD) stage-specific transition probabilities for disease progression based on Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. These were internally validated in 50% training and 50% testing datasets and further validated in national administrative datasets (N=73,256). A cost-effectiveness and budget impact analysis for a hypothetical intervention of sodium-glucose cotransporter 2 inhibitors (SGLT2is) was conducted from a healthcare system perspective, across different time horizons, in low-risk (G0-G2) and high-risk individuals (G3-G4) based on eGFR-defined DKD risk stages.
resultsAnnually, more than half of the participants (53.0-88.8%) stayed in the same DKD stage, with the probabilities of progressing or regressing to the next DKD stage being highest between stages G0 and G1. The SGLT2i intervention was cost-effective when given in low-risk, but not in high-risk, individuals with type 2 diabetes in both the short and the long term. Additionally, implementing the SGLT2i intervention would incur a 5 year cumulative cost increase of 41.5%, assuming an annual 5% increase in market uptake. CONCLUSIONS/
interpretationWe developed a robust model of DKD progression based on real-world data and demonstrated its value through economic modelling of risk-stratified interventions with known effectiveness. This model can aid policymakers and health professionals in evaluating population-level interventions for evidence-based policy decisions.
Indexed as
Identifiers
40739365What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.